Last reviewed · How we verify
Sierra Oncology LLC - a GSK company — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Placebo to match danazol | Placebo to match danazol | phase 3 | Oncology | |||
| Placebo to match ruxolitinib | Placebo to match ruxolitinib | phase 3 | Oncology |
Therapeutic area mix
- Oncology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Sierra Oncology LLC - a GSK company:
- Sierra Oncology LLC - a GSK company pipeline updates — RSS
- Sierra Oncology LLC - a GSK company pipeline updates — Atom
- Sierra Oncology LLC - a GSK company pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Sierra Oncology LLC - a GSK company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sierra-oncology-llc-a-gsk-company. Accessed 2026-05-17.